Vita Coco Company, Inc. (COCO) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -29.41%. A quarter ago, it was expected that this company would post earnings of $0.32 per share when it actually produced earnings of $0.4, delivering a surprise of +25%.Over the last four quarters, the co ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Monster Beverage (MNST) - Monster Beverage currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating a favorable outlook for the stock [2][3] - The stock has shown significant price performance, with a 2.2% increase over the past week and an 11.74% increase over the past quarter, outperforming the S&P 500's 1.65% increase in the same period [5][6] Industry Comparison - The Zacks Beverages - Soft drinks industry has seen a 3.53% increase over the past week, while Monster Beverage's monthly price change of 3.94% is slightly better than the industry's 3.79% performance [5] Trading Volume - The average 20-day trading volume for Monster Beverage is 6,328,270 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - Over the past two months, one earnings estimate for Monster Beverage has increased, raising the consensus estimate from $1.98 to $1.99, with two upward revisions for the next fiscal year and no downward revisions [9] Conclusion - Given the positive momentum indicators and earnings outlook, Monster Beverage is positioned as a strong buy candidate with a Momentum Score of B [11]

Coca-Cola (KO) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.66%. A quarter ago, it was expected that this world's largest beverage maker would post earnings of $0.78 per share when it actually produced earnings of $0.82, delivering a surprise of +5.13%.Over the last four quarter ...

Core Viewpoint - Luckin Coffee Inc. has shown significant stock performance with a recent increase of 5.7% to $36.87, driven by strong trading volume and positive growth indicators [1]. Company Performance - The company is leveraging a robust digital model, strategic pricing, and store expansion, along with efficient small-format outlets to enhance customer engagement and drive growth in the coffee market [2]. - Upcoming quarterly earnings are projected at $0.43 per share, reflecting a year-over-year increase of 7.5%, while revenues are expected to reach $1.9 billion, marking a 44.1% increase from the previous year [3]. Earnings Estimates and Stock Trends - The consensus EPS estimate for Luckin Coffee has remained stable over the last 30 days, indicating that stock price movements may not sustain without changes in earnings estimate revisions [4]. - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the context of the beverages-soft drinks industry [4].

Core Viewpoint - Vita Coco Company, Inc. is experiencing fluctuations in stock performance and is set to report earnings that reflect both growth and challenges in revenue [1][2][3]. Group 1: Stock Performance - The stock closed at $55.00, down 4.45% from the previous day, underperforming the S&P 500's loss of 0.51% [1]. - Over the past month, shares have appreciated by 10.71%, outperforming the Consumer Staples sector's gain of 10.05% and the S&P 500's gain of 0.93% [1]. Group 2: Earnings Forecast - The upcoming earnings report is expected to show an EPS of $0.13, reflecting an 8.33% increase from the same quarter last year [2]. - Revenue is projected at $126.87 million, a decrease of 0.33% compared to the previous year [2]. Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $1.23 per share, indicating a growth of 14.95%, while revenue is expected to remain flat at $608.87 million [3]. - Recent analyst estimate revisions suggest optimism regarding the company's near-term business trends [3]. Group 4: Valuation Metrics - The current Forward P/E ratio for Vita Coco is 36.37, significantly higher than the industry average of 18.66, indicating a premium valuation [6]. - The PEG ratio stands at 1.63, compared to the industry average of 2.13, suggesting a more favorable growth outlook relative to peers [7]. Group 5: Industry Context - The Beverages - Soft drinks industry, which includes Vita Coco, ranks in the bottom 39% of all industries according to the Zacks Industry Rank [7]. - The Zacks Rank system currently rates Vita Coco at 4 (Sell), reflecting a stagnant EPS estimate over the past month [5].

PepsiCo (PEP) came out with quarterly earnings of $2.26 per share, beating the Zacks Consensus Estimate of $2.24 per share. This compares to earnings of $1.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.09%. A quarter ago, it was expected that this food and beverage company would post earnings of $2.27 per share when it actually produced earnings of $2.29, delivering a surprise of +0.88%.Over the last four quarters, the ...

Core Viewpoint - Vita Coco Company, Inc. is experiencing a mixed performance in the stock market, with a recent decline in stock price and upcoming earnings report that is anticipated to show modest growth in earnings but a slight decrease in revenue [1][2]. Company Performance - The stock closed at $54.17, down by 1.47% from the previous day, underperforming the S&P 500's loss of 0.01% [1]. - Over the past month, the stock has increased by 2.9%, which is lower than the Consumer Staples sector's gain of 4.93% and higher than the S&P 500's gain of 0.78% [1]. Earnings Estimates - The upcoming earnings report is projected to show earnings of $0.13 per share, reflecting a year-over-year growth of 8.33% [2]. - The consensus estimate for revenue is $126.87 million, indicating a 0.33% decrease compared to the same quarter last year [2]. - For the entire fiscal year, earnings are estimated at $1.23 per share, representing a growth of 14.95%, while revenue is projected to remain unchanged at $608.87 million [3]. Analyst Estimates and Rankings - Recent adjustments to analyst estimates suggest a favorable outlook on the company's business health and profitability [4]. - The Zacks Rank system currently rates Vita Coco Company, Inc. at 4 (Sell), indicating a less favorable investment outlook [6]. Valuation Metrics - The company has a Forward P/E ratio of 34.74, which is significantly higher than the industry average of 17.44 [7]. - The PEG ratio stands at 1.56, compared to the average PEG ratio of 2.12 for the Beverages - Soft drinks industry [8]. Industry Context - The Beverages - Soft drinks industry is part of the Consumer Staples sector and currently holds a Zacks Industry Rank of 215, placing it in the bottom 13% of all industries [9].

Core Viewpoint - As the stock market approaches all-time highs, investors are looking for defensive options, with Coca-Cola and Pepsi being prime candidates due to their consistent performance during market corrections [1] Company Performance - Coca-Cola's return on invested capital (ROIC) is 18%, showing a positive trend towards 20% or higher, while Pepsi's ROIC is at 14%, indicating a decline in recent quarters [3][4] - Coca-Cola's fiscal 2025 earnings per share (EPS) rose 3% to $2.98, with a projected 8% increase to $3.22 for FY26, alongside a sales increase of 3% for FY25 and a projected 5% increase to $51.01 billion for FY26 [6] - Pepsi's FY25 EPS is expected to slightly dip to $8.12 but is projected to rebound by 5% to $8.55 in FY26, with sales expected to rise 2% for FY25 and 4% to $97.07 billion in FY26 [9] Valuation and Dividend Analysis - Pepsi trades at 16 times forward earnings and near 2 times forward sales, aligning with industry averages, while Coca-Cola trades at a premium of 6 times forward sales [10] - Coca-Cola offers a 3% annual dividend yield, matching the industry average, while Pepsi has a higher yield of 4%, with both companies classified as "Dividend Kings" for increasing dividends for over 50 consecutive years [12] Investment Outlook - As 2026 begins, Pepsi appears to meet more investor criteria despite Coca-Cola's stronger ROIC, with Coca-Cola potentially facing short-term weakness due to its higher valuation compared to Pepsi and its beverage peers [13]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] Company Overview: Monster Beverage (MNST) - Monster Beverage currently holds a Momentum Style Score of B and a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance [2][3] - The stock has shown a price increase of 3.1% over the past week, while the Zacks Beverages - Soft drinks industry has declined by 2.07% during the same period [5] - Over the past quarter, Monster Beverage shares have risen by 14.56%, and by 46.99% over the last year, significantly outperforming the S&P 500, which increased by 5.23% and 16.06% respectively [6] Trading Volume - The average 20-day trading volume for Monster Beverage is 5,067,165 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the last two months, 8 earnings estimates for Monster Beverage have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $1.91 to $1.99 [9] - For the next fiscal year, 9 estimates have also moved upwards without any downward revisions [9] Conclusion - Given the positive momentum indicators and earnings outlook, Monster Beverage is positioned as a strong buy candidate for investors seeking short-term opportunities [11]

Core Insights - The Zacks Equity Research team has highlighted several stocks, including AbbVie Inc., The Coca-Cola Co., Chevron Corp., ImmuCell Corp., and Precipio, Inc., in their Analyst Blog [1][2]. AbbVie Inc. (ABBV) - AbbVie has outperformed the Zacks Large Cap Pharmaceuticals industry over the past year, with a share price increase of +31.6% compared to the industry’s +19.5% [4]. - The company has successfully managed the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are performing well and expected to support revenue growth [4][5]. - AbbVie is returning to robust revenue growth in 2025, following the U.S. Humira loss of exclusivity, and has been actively acquiring companies to enhance its early-stage pipeline [5]. The Coca-Cola Co. (KO) - Coca-Cola's shares have outperformed the Zacks Beverages - Soft Drinks industry over the past year, with a gain of +14.5% compared to +10.5% for the industry [6]. - The company's performance is attributed to solid organic revenue growth, effective pricing strategies, and gains in global market share within the non-alcoholic ready-to-drink category [6][7]. - Ongoing innovation and digital transformation efforts are enhancing Coca-Cola's competitive edge, although the company faces challenges such as soft volumes in key regions and currency headwinds [7][8]. Chevron Corp. (CVX) - Chevron's shares have increased by +9.5% over the past year, while the Zacks Oil and Gas - Integrated - International industry has gained +16% [9]. - The acquisition of Hess has significantly improved Chevron's growth outlook by adding high-quality assets in regions like Guyana and the Gulf of Mexico [9]. - The Permian Basin remains a key asset for Chevron, driving consistent growth, although challenges such as lower crude realizations and regulatory issues in California temper optimism [10]. ImmuCell Corp. (ICCC) - ImmuCell has outperformed the Zacks Medical - Products industry with a share price increase of +26.3% compared to +1% for the industry [11]. - The company’s First Defense franchise leads the market in calf scours prevention, with Tri-Shield accounting for 70% of volume and a 48% market share [11][12]. - ImmuCell has resolved operational bottlenecks, restoring capacity to $30 million in annual sales, with TTM revenues of $27.8 million, reflecting a 16% year-over-year increase [12][13]. Precipio, Inc. (PRPO) - Precipio's shares have surged by +361.2% over the past year, significantly outperforming the Zacks Medical Info Systems industry, which saw a decline of -1.3% [14]. - The company is moving towards self-funded growth, driven by its Pathology Services division, which is experiencing steady organic growth and rising margins [14][15]. - Precipio has improved profitability and cash flow, although it faces risks related to liquidity and regulatory uncertainties [15][16].